Back to top

immuno-therapy: Archive

Zacks Equity Research

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.

CGENPositive Net Change ANVSPositive Net Change ALXONegative Net Change IBRXPositive Net Change